Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.14 USD
−22.26 M USD
0.00 USD
8.56 M
About Nuvectis Pharma, Inc.
Sector
CEO
Ronald E. Bentsur
Headquarters
Fort Lee
Website
Founded
2020
FIGI
BBG012BCR149
Nuvectis Pharma, Inc. is a preclinical stage biopharmaceutical company. It focuses on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its product pipeline includes NXP800 and NXP900. The company was founded by Ron Bentsur, Enrique Poradosu and Shay Shemesh on July 27, 2020 and is headquartered in Fort Lee, NJ.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of NVCT is 5.04 USD — it has decreased by −4.55% in the past 24 hours. Watch Nuvectis Pharma, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Nuvectis Pharma, Inc. stocks are traded under the ticker NVCT.
NVCT stock has risen by 2.02% compared to the previous week, the month change is a −35.80% fall, over the last year Nuvectis Pharma, Inc. has showed a −36.75% decrease.
We've gathered analysts' opinions on Nuvectis Pharma, Inc. future price: according to them, NVCT price has a max estimate of 25.00 USD and a min estimate of 20.00 USD. Watch NVCT chart and read a more detailed Nuvectis Pharma, Inc. stock forecast: see what analysts think of Nuvectis Pharma, Inc. and suggest that you do with its stocks.
NVCT reached its all-time high on May 18, 2022 with the price of 20.92 USD, and its all-time low was 3.08 USD and was reached on Feb 4, 2022. View more price dynamics on NVCT chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
NVCT stock is 9.82% volatile and has beta coefficient of 3.24. Track Nuvectis Pharma, Inc. stock price on the chart and check out the list of the most volatile stocks — is Nuvectis Pharma, Inc. there?
Today Nuvectis Pharma, Inc. has the market capitalization of 97.38 M, it has decreased by −1.01% over the last week.
Yes, you can track Nuvectis Pharma, Inc. financials in yearly and quarterly reports right on TradingView.
Nuvectis Pharma, Inc. is going to release the next earnings report on Mar 11, 2025. Keep track of upcoming events with our Earnings Calendar.
NVCT earnings for the last quarter are −0.24 USD per share, whereas the estimation was −0.25 USD resulting in a 4.91% surprise. The estimated earnings for the next quarter are −0.25 USD per share. See more details about Nuvectis Pharma, Inc. earnings.
Nuvectis Pharma, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
NVCT net income for the last quarter is −4.15 M USD, while the quarter before that showed −4.43 M USD of net income which accounts for 6.21% change. Track more Nuvectis Pharma, Inc. financial stats to get the full picture.
No, NVCT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 1, 2024, the company has 13.00 employees. See our rating of the largest employees — is Nuvectis Pharma, Inc. on this list?
Like other stocks, NVCT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Nuvectis Pharma, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Nuvectis Pharma, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Nuvectis Pharma, Inc. stock shows the strong sell signal. See more of Nuvectis Pharma, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.